Works matching IS 11738804 AND DT 2021 AND VI 35 AND IP 3
Results: 9
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study.
- Published in:
- BioDrugs, 2021, v. 35, n. 3, p. 325, doi. 10.1007/s40259-021-00482-x
- By:
- Publication type:
- Article
Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration.
- Published in:
- BioDrugs, 2021, v. 35, n. 3, p. 303, doi. 10.1007/s40259-021-00481-y
- By:
- Publication type:
- Article
Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.
- Published in:
- BioDrugs, 2021, v. 35, n. 3, p. 255, doi. 10.1007/s40259-021-00480-z
- By:
- Publication type:
- Article
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey.
- Published in:
- BioDrugs, 2021, v. 35, n. 3, p. 363, doi. 10.1007/s40259-021-00479-6
- By:
- Publication type:
- Article
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.
- Published in:
- BioDrugs, 2021, v. 35, n. 3, p. 281, doi. 10.1007/s40259-021-00477-8
- By:
- Publication type:
- Article
Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
- Published in:
- 2021
- By:
- Publication type:
- Letter
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
- Published in:
- BioDrugs, 2021, v. 35, n. 3, p. 337, doi. 10.1007/s40259-021-00475-w
- By:
- Publication type:
- Article
Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
- Published in:
- 2021
- By:
- Publication type:
- Letter
Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators.
- Published in:
- BioDrugs, 2021, v. 35, n. 3, p. 351, doi. 10.1007/s40259-021-00478-7
- By:
- Publication type:
- Article